The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...
1d
Zacks Investment Research on MSNCan BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...
St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
10dOpinion
MedPage Today on MSNHow a Book Is Undermining Progress Against Alzheimer'sSystematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...
The Therapeutic Goods Administration (TGA) of Australia has declined the approval of Leqembi (lecanemab) as a treatment for ...
8d
GlobalData on MSNUK’s pricing watchdog rejects Alzheimer treatments for the second timeThis is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and ...
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results